STOCK TITAN
  1. Home
  2. News
  3. ALT

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.

Altimmune management will host a conference call at 8:30 am E.T. on March 15 to discuss financial results and provide a business update.

Conference Call Information:
  
Date:
Time:
Domestic Dial-in:
International Dial-in:
Conference ID:
Webcast:
Tuesday, March 15
8:30 am Eastern Time
(844) 615-6509
(918) 922-3148
4557398
https://edge.media-server.com/mmc/p/5www3cgz
  

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com


Stock ALT logo
Altimmune Inc

NASDAQ:ALT

ALT Rankings

#2960 Ranked by Market Cap
#5342 Ranked by Stock Gains
N/A Ranked by Dividends

ALT Latest News

Mar 27, 2024
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 20, 2024
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
Jan 2, 2024
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
Nov 30, 2023
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Nov 7, 2023
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

ALT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Commercial Services, Miscellaneous Commercial Services, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Gaithersburg

About ALT

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current